

Glossary

Where applicable, definitions from RECIST criteria have been used

Adriamycin[®]: brand name for the chemotherapy drug doxorubicin

AJCC: American Joint Committee on Cancer

APR: abdominoperineal resection

ASPS: alveolar soft-part sarcoma

Bevacizumab: the generic name for Avastin[®]

CCS: clear cell sarcoma

CDDP: *cis*-diamminedichloroplatinum(II)

Cediranib: a tyrosine kinase inhibitor no longer in clinical development

CGH: comparative genomic hybridisation

CMT: combined modality therapy

CPG: clinical practice guidelines

CR: complete response, defined as the disappearance of all target lesions

CT: computed tomography

CT: chemotherapy

CTV: clinical target volume

DFSP: dermatofibrosarcoma protuberans

DCR: disease control rate, defined as CR + PR + SD

Doxorubicin: the generic name for Adriamycin[®]

DTIC: dacarbazine

Dynamic contrast-enhanced MRI: a method which enables analysis of blood vessels generated by a tumour

E-GIST: extragastrointestinal stromal tumour

Erlotinib: EGFR (Epidermal growth factor receptor) inhibitor. Brand name Tarceva[®]

FNA: fine needle aspiration

Gardner syndrome: an autosomal dominant form of polyposis characterised by the presence of multiple polyps in the colon together with tumors outside the colon. Also known as familial colorectal polyposis

G-CSF: granulocyte colony-stimulating factor

GemTax: chemotherapy regimen combining gemcitabine and docetaxel

GIST: gastrointestinal stromal tumour

GTV: gross tumour volume

HDR: high dose rate

HPF: high-power fields

Ifos: Ifosfamide. Brand name Ifex[®]

ILP: isolated limb perfusion

Imatinib: a tyrosine kinase inhibitor. Brand names Gleevec[®] and Glivec[®]

IMRT: intensity-modulated radiation therapy

LDR: low dose rate

Li-Fraumeni syndrome: extremely rare syndrome linked to germline mutations of the TP53 tumour suppressor gene, which normally helps control cell growth

LR: local relapse

MAID: drug combination comprising of mesna, adriamycin, ifosfamide, dacarbazine

MFH: malignant fibrous histiocytoma

MLS: myxoid liposarcoma

MPNST: malignant peripheral nerve sheath tumour

MRI: magnetic resonance imaging

NHL: non-Hodgkin lymphoma

NOS: not otherwise specified

NR: statistical significance not reached

ORR: objective response rate, defined as the total number of patients with either a CR or PR

OS: overall survival, defined as the percentage of subjects in a study who have survived for a defined period of time

Pazopanib: multi-kinase inhibitor. Brand name Votrient[®]

PD: progressive disease, defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions

PDGFR: platelet-derived growth factor receptor

PET: positron emission tomography

PFS: progression-free survival, defined as the length of time during and after treatment during which the cancer does not worsen

PNET: primitive neuroectodermal tumour

PR: partial response, defined as a decrease in tumour size of at least 30% in response to treatment

PTV: planning target volume

PVNS: pigmented villonodular synovitis

RAS: radiation-associated sarcoma

RECIST: Response Evaluation Criteria in Solid Tumours

RFA: radiofrequency ablation

RT: radiotherapy

SD: stable disease, defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter since the treatment started

SEER: surveillance, epidemiology and end results

SFT: solitary fibrous tumour

STBS: soft tissue and bone sarcoma

Sunitinib: a multi kinase inhibitor. Brand name Sutent[®]

Temozolomide: oral alkylating agent. Brand names Temodar[®], Temodal[®] and Temcad[®]

TKI: tyrosine kinase inhibitor

Topotecan: chemotherapy agent. Brand name Hycamtin[®]

Trabectedin: anti-tumour agent. Brand name Yondelis[®]

UICC: Union for International Cancer Control

UPS: undifferentiated pleomorphic sarcoma

VATS: video-assisted thoracoscopic surgery

VIDE: chemotherapy regimen combining vincristine, ifosfamide, doxorubicin and etoposide

Vincristine: a mitotic inhibitor, sometimes abbreviated to 'VCR'. Brand name Oncovin[®]